RebrAIn receives second FDA clearance to optimise targeting in neurosurgery

RebrAIn has received a second FDA 510(k) clearance for its OptimMRI software which is designed to optimise targeting in stereotactic and functional neurosurgery.

The OptimMRI software includes a new machine learning model to assist in targeting the infero-lateral part of the VIM for lesioning techniques such as MRgFUS and radiosurgery.

This new software version already features FDA-cleared machine learning models for the subthalamic nucleus (STN) and ventral intermediate nucleus (VIM) regions of interest to assist in targeting Deep Brain Stimulation (DBS).

David Caumartin, CEO of RebrAIn, a precision neuro-surgery platform company, stated: “Our extension to US customers to better plan targets for lesioning is a significant step in RebrAIn’s growth and strategic transformation. The US market represents the largest opportunity to enable personalised targeting for neurological disorders such as Essential Tremor.

“The ability to offer AI clinical targeting to neurosurgical suites will open many collaborations nationwide, which today are treated with DBS and MR-guided focused ultrasound.

“Since our recent discussions at US congresses, it was necessary for us to offer neurosurgeons a complete service.”

RebrAIn’s co-founders, Prof. Emmanuel Cuny MD and Prof. Nejib Zemzemi PhD, will be presenting on “VIM Lesions in Radiosurgery and Focused Ultrasound: Assessment of the Accuracy of Two Targeting Models Based on Machine Learning” at the World Society for Stereotactic and Functional Neurosurgery (WSSFN) biennial meeting in Chicago, IL, on September 5, 2024.